Advertisement

Advertisement

APRE Stock Latest News

Aprea Therapeutics files to sell 74.35M shares of common stock for holders

The FlyAprea Therapeutics files to sell 74.35M shares of common stock for holders

Aprea Therapeutics: Positive Read‑Through From Zentalis and Improving WEE1 Sentiment Support Buy Rating and $5 Target

PremiumRatings

Aprea Therapeutics: Positive Read‑Through From Zentalis and Improving WEE1 Sentiment Support Buy Rating and $5 Target

16d ago

Aprea Therapeutics Raises $30M to Advance Oncology Pipeline

PremiumCompany Announcements

Aprea Therapeutics Raises $30M to Advance Oncology Pipeline

29d ago

Aprea Therapeutics price target lowered to $1.20 from $4 at H.C. Wainwright

PremiumThe Fly

Aprea Therapeutics price target lowered to $1.20 from $4 at H.C. Wainwright

1M ago

Aprea Therapeutics Announces $30 Million Private Placement

PremiumCompany Announcements

Aprea Therapeutics Announces $30 Million Private Placement

1M ago

Aprea Therapeutics confirms partial response in ongoing ACESOT-1051 trial

PremiumThe FlyAprea Therapeutics confirms partial response in ongoing ACESOT-1051 trial

1M ago

Aprea Highlights Early APR-1051 Data and Financial Update

Company Announcements

Aprea Highlights Early APR-1051 Data and Financial Update

2M ago

Aprea Therapeutics reports Q4 EPS (32c) vs. (49c) last year

The Fly

Aprea Therapeutics reports Q4 EPS (32c) vs. (49c) last year

2M ago

Aprea Therapeutics sees cash runway into 1Q27

PremiumThe Fly

Aprea Therapeutics sees cash runway into 1Q27

2M ago

Aprea Therapeutics files to sell 12.58M shares of common stock for holders

PremiumThe Fly

Aprea Therapeutics files to sell 12.58M shares of common stock for holders

2M ago

Aprea Therapeutics: Emerging Dose-Responsive Efficacy and Favorable Safety of APR-1051 Underpin Buy Rating

PremiumRatings

Aprea Therapeutics: Emerging Dose-Responsive Efficacy and Favorable Safety of APR-1051 Underpin Buy Rating

2M ago

Aprea Highlights Encouraging Phase 1 Data for APR-1051

PremiumCompany Announcements

Aprea Highlights Encouraging Phase 1 Data for APR-1051

2M ago

Aprea Therapeutics announces additional clinical activity for APR-1051

PremiumThe FlyAprea Therapeutics announces additional clinical activity for APR-1051

2M ago

Aprea announces expansions of its global intellectual property estate

The Fly

Aprea announces expansions of its global intellectual property estate

3M ago

Ratings

APR-1051’s Emerging Best-in-Class WEE1 Profile Underpins Buy Rating on Aprea Therapeutics

3M ago

Aprea Therapeutics price target lowered to $7 from $11 at Wedbush

PremiumThe Fly

Aprea Therapeutics price target lowered to $7 from $11 at Wedbush

3M ago

Aprea Therapeutics appoints Kennedy as Chief Medical Advisor

PremiumThe Fly

Aprea Therapeutics appoints Kennedy as Chief Medical Advisor

3M ago

Aprea Therapeutics Announces Financing and Early Trial Response

PremiumCompany Announcements

Aprea Therapeutics Announces Financing and Early Trial Response

3M ago

Aprea Therapeutics price target lowered to $4 from $5 at H.C. Wainwright

PremiumThe Fly

Aprea Therapeutics price target lowered to $4 from $5 at H.C. Wainwright

3M ago

Aprea Therapeutics prices 6.29M shares at 89c in private placement

PremiumThe FlyAprea Therapeutics prices 6.29M shares at 89c in private placement

3M ago

Aprea Therapeutics announces early PoC data in ACESOT-1051 trial

The Fly

Aprea Therapeutics announces early PoC data in ACESOT-1051 trial

3M ago

Aprea Therapeutics Updates Oncology Pipeline and Strategy Outlook

Company Announcements

Aprea Therapeutics Updates Oncology Pipeline and Strategy Outlook

4M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >